GUJARAT THEMIS BIOSYN
|
GUJARAT THEMIS BIOSYN Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.14 | 39.90 | 30.03 | 20.77 | 16.30 |
| CEPS(Rs) | 5.75 | 5.56 | 4.21 | 2.93 | 2.30 |
| DPS(Rs) | 1.00 | 5.40 | 11.00 | - | 1.65 |
| Book NAV/Share(Rs) | 27.72 | 102.66 | 71.12 | 48.14 | 29.04 |
| Tax Rate(%) | 25.43 | 25.17 | 26.10 | 26.18 | 24.26 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 46.36 | 49.62 | 50.54 | 44.53 | 37.40 |
| EBIT Margin(%) | 46.85 | 52.32 | 52.12 | 46.23 | 37.80 |
| Pre Tax Margin(%) | 46.72 | 52.21 | 51.40 | 45.14 | 36.72 |
| PAT Margin (%) | 34.84 | 39.07 | 37.98 | 33.32 | 27.81 |
| Cash Profit Margin (%) | 36.92 | 40.80 | 39.93 | 35.24 | 29.41 |
| Performance Ratios | |||||
| ROA(%) | 27.65 | 35.81 | 37.08 | 35.65 | 45.62 |
| ROE(%) | 33.76 | 45.92 | 50.35 | 53.82 | 77.99 |
| ROCE(%) | 45.40 | 61.51 | 67.91 | 67.89 | 85.96 |
| Asset Turnover(x) | 0.79 | 0.92 | 0.98 | 1.07 | 1.64 |
| Sales/Fixed Asset(x) | 3.57 | 4.11 | 4.27 | 3.82 | 4.25 |
| Working Capital/Sales(x) | 5.41 | 3.19 | 1.88 | 1.91 | 7.22 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.28 | 0.24 | 0.23 | 0.26 | 0.24 |
| Receivable days | 48.29 | 52.91 | 63.29 | 70.42 | 55.80 |
| Inventory Days | 19.29 | 32.26 | 28.06 | 24.34 | 13.65 |
| Payable days | 99.37 | 114.42 | 115.10 | 132.50 | 215.31 |
| Valuation Parameters | |||||
| PER(x) | 48.64 | 3.44 | 13.57 | 9.80 | 5.96 |
| PCE(x) | 45.89 | 16.47 | 12.91 | 9.27 | 5.64 |
| Price/Book(x) | 14.29 | 6.69 | 5.73 | 4.23 | 3.35 |
| Yield(%) | 0.25 | 0.79 | 2.70 | - | 1.70 |
| EV/Net Sales(x) | 16.90 | 6.66 | 5.05 | 3.00 | 1.73 |
| EV/Core EBITDA(x) | 34.53 | 12.32 | 9.33 | 6.22 | 4.39 |
| EV/EBIT(x) | 36.06 | 12.72 | 9.68 | 6.48 | 4.58 |
| EV/CE(x) | 14.25 | 6.62 | 5.61 | 3.72 | 2.93 |
| M Cap / Sales | 16.94 | 6.72 | 5.15 | 3.27 | 1.66 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 14.45 | 29.19 | 26.82 | 6.39 | 107.37 |
| Core EBITDA Growth(%) | 3.59 | 29.18 | 42.43 | 29.97 | 250.30 |
| EBIT Growth(%) | 2.48 | 29.70 | 42.99 | 30.09 | 285.20 |
| PAT Growth(%) | 2.06 | 32.88 | 44.55 | 27.48 | 269.40 |
| EPS Growth(%) | -79.59 | 32.88 | 44.55 | 27.47 | 269.40 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | 0.04 | 0.19 |
| Current Ratio(x) | 1.87 | 2.30 | 2.93 | 2.84 | 1.49 |
| Quick Ratio(x) | 1.78 | 1.89 | 2.57 | 2.60 | 1.24 |
| Interest Cover(x) | 347.14 | 440.64 | 72.31 | 42.66 | 34.85 |
| Total Debt/Mcap(x) | - | - | - | 0.01 | 0.06 |
Compare Financial Ratios of peers of GUJARAT THEMIS BIOSYN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GUJARAT THEMIS BIOSYN | ₹3,882.0 Cr | -4.2% | 1.9% | 11.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹383,570.0 Cr | -1.9% | -4.1% | -6.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹162,808.0 Cr | -3.6% | -12.3% | 27.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,734.0 Cr | -2.1% | 7.2% | 9.3% | Stock Analytics | |
| CIPLA | ₹120,468.0 Cr | -0.7% | -0% | -2.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,212.0 Cr | -1.6% | -5.4% | -12.1% | Stock Analytics | |
GUJARAT THEMIS BIOSYN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GUJARAT THEMIS BIOSYN | -4.2% |
1.9% |
11.5% |
| SENSEX | -0.7% |
-3.7% |
2.4% |
You may also like the below Video Courses
